姜黄素
溃疡性结肠炎
医学
姜黄
药理学
炎症性肠病
MAPK/ERK通路
结肠炎
内科学
免疫学
激酶
疾病
传统医学
生物
细胞生物学
作者
Manjeshwar Shrinath Baliga,Nandhini Joseph,Marikunte V Venkataranganna,Arpit Saxena,Ponemone Venkatesh,Raja Fayad
出处
期刊:Food & Function
[The Royal Society of Chemistry]
日期:2012-01-01
卷期号:3 (11): 1109-1109
被引量:112
摘要
Inflammatory bowel disease (IBD) comprising of ulcerative colitis (UC) and Crohn's disease (CD) is a major ailment affecting the small and large bowel. In clinics, IBD is treated using 5-amninosalicylates, antibiotics, the steroids and immunomodulators. Unfortunately, the long term usages of these agents are associated with undue side effects and compromise the therapeutic advantage. Accordingly, there is a need for novel agents that are effective, acceptable and non toxic to humans. Preclinical studies in experimental animals have shown that curcumin, an active principle of the Indian spice turmeric (Curcuma longa Linn) is effective in preventing or ameliorating UC and inflammation. Over the last few decades there has been increasing interest in the possible role of curcumin in IBD and several studies with various experimental models of IBD have shown it to be effective in mediating the inhibitory effects by scavenging free radicals, increasing antioxidants, influencing multiple signaling pathways, especially the kinases (MAPK, ERK), inhibiting myeloperoxidase, COX-1, COX-2, LOX, TNF-α, IFN-γ, iNOS; inhibiting the transcription factor NF-κB. Clinical studies have also shown that co-administration of curcumin with conventional drugs was effective, to be well-tolerated and treated as a safe medication for maintaining remission, to prevent relapse and improve clinical activity index. Large randomized controlled clinical investigations are required to fully understand the potential of oral curcumin for treating IBD.
科研通智能强力驱动
Strongly Powered by AbleSci AI